BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23278369)

  • 1. Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications.
    Karaca-Mandic P; Swenson T; Abraham JM; Kane RL
    Health Serv Res; 2013 Aug; 48(4):1311-33. PubMed ID: 23278369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncompliance in the use of cardiovascular medications in the Medicare Part D population.
    Blackwell SA; Baugh DK; Montgomery MA; Ciborowski GM; Waldron CJ; Riley GF
    Medicare Medicaid Res Rev; 2011 Dec; 1(4):. PubMed ID: 22340781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.
    Riley GF; Warren JL; Harlan LC; Blackwell SA
    Medicare Medicaid Res Rev; 2011 Dec; 1(4):. PubMed ID: 22340780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of medication synchronization programs on proportion of days covered (PDC) scores and Medicare Part D medication-related adherence metrics.
    Bernard K; Cowles B; McCall K; Henningsen RM; O'Toole M; Tu C
    J Am Pharm Assoc (2003); 2019; 59(3):343-348. PubMed ID: 30940515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes.
    Davidoff A; Lopert R; Stuart B; Shaffer T; Lloyd JT; Shoemaker JS
    Value Health; 2012 May; 15(3):404-11. PubMed ID: 22583449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare Part D's Effects on Drug Utilization and Out-of-Pocket Costs: A Systematic Review.
    Park YJ; Martin EG
    Health Serv Res; 2017 Oct; 52(5):1685-1728. PubMed ID: 27480577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
    Cheng LI; Rascati KL
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonlinear pricing in drug benefits and medication use: the case of statin compliance in Medicare Part D.
    Jung K; Feldman R; McBean AM
    Health Serv Res; 2014 Jun; 49(3):910-28. PubMed ID: 24354765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of an intervention to increase statin use in medicare members who qualified for a medication therapy management program.
    Stockl KM; Tjioe D; Gong S; Stroup J; Harada AS; Lew HC
    J Manag Care Pharm; 2008; 14(6):532-40. PubMed ID: 18693777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of formulary restrictions on medication use and costs.
    Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
    Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
    Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication Nonadherence: The Role of Cost, Community, and Individual Factors.
    Abbass I; Revere L; Mitchell J; Appari A
    Health Serv Res; 2017 Aug; 52(4):1511-1533. PubMed ID: 27558760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to oral osteoporosis drugs among female Medicare Part D beneficiaries.
    Lin CW; Karaca-Mandic P; McCullough JS; Weaver L
    Womens Health Issues; 2014; 24(4):e435-45. PubMed ID: 24837398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
    Stuart B; Hendrick FB; Xu J; Dougherty JS
    Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.
    Frankenfield DL; Weinhandl ED; Powers CA; Howell BL; Herzog CA; St Peter WL
    Am J Kidney Dis; 2012 May; 59(5):670-81. PubMed ID: 22206743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease.
    Wei YJ; Palumbo FB; Simoni-Wastila L; Shulman LM; Stuart B; Beardsley R; Brown C
    Clin Ther; 2013 Oct; 35(10):1513-1525.e1. PubMed ID: 24139423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
    Odouard IC; Anderson GF; Alexander GC; Ballreich J
    J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.